<DOC>
	<DOCNO>NCT00293137</DOCNO>
	<brief_summary>The principal aim investigate safety efficacy rosiglitazone patient chronic systolic heart ( Dilated cardiomyopathy ) . We hypothesize patient heart failure , rosiglitazone safe , reduce nitric oxide ( NO ) derive oxidative stress ( particular , nitrotyrosine ) thereby improve endothelial dysfunction , leave ventricular performance , metabolic parameter .</brief_summary>
	<brief_title>NORDIC : Nitric Oxide-Derived Oxidants Regional Endothelial Diastolic Dysfunction Dilated Cardiomyopathy</brief_title>
	<detailed_description>The study single center , double-blind , prospective placebo control trial 60 non-diabetic heart failure patient . Prior administration study medication , medical history , physician exam , blood draw , laser Doppler imaging ( Periscan system ) , venous occlusion strain gauge plethysmography , metabolic exercise stress test 2D 3D echocardiogram perform . Patients randomize receive rosiglitazone 2mg/day oral versus placebo up-titration 4mg/day oral versus placebo 3 month . Each study arm 30 patient participate 6 month . Follow assessment complete 6 week , 3 month 6 month post randomization .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Cardiomyopathy , Dilated</mesh_term>
	<mesh_term>Heart Failure , Systolic</mesh_term>
	<mesh_term>Nitric Oxide</mesh_term>
	<criteria>Patients enrol trial must meet following criterion : 1 . Chronic , stable , euvolemic , heart failure optimally treat least 3 month stable dos ACE inhibitor angiotensinreceptor blocker betablockers 2 . Mildtomoderate sign and/or symptom heart failure ( NYHA functional Class III ) 3 . Left ventricular ejection fraction &lt; 40 % echocardiogram within 6 month randomization enrollment Patients meet one follow criterion eligible randomization trial : 1 . Known confirm newlydiagnosed diabetes mellitus ( 2004 ADA criterion ) 2 . Major cardiovascular event ( myocardial infarction , unstable angina , stroke , transient ischemic attack , pulmonary embolism ) , major surgery &lt; 1 month enrollment 3 . Hospitalization emergency room visit heart failure exacerbation , use inotropic agent &lt; 1 month 4 . NYHA class III IV 5 . Current treatment thiazolidinediones 6 . Allergy rosiglitazone , liver insufficiency ( ALT &gt; 2.5x upper limit normal ) 7 . Heart failure due congenital heart disease , primary valvular disease , hypertrophic cardiomyopathy , heart failure cause know cardiotoxic agent ( e.g . adriamycin ) 8 . Endstage renal failure renal replacement therapy ( dialysis ) 9 . Life expectancy , expect cardiac transplantation within 12 month enrollment 10 . Women pregnant , plan become pregnant lactating . Women childbearing potential must negative serum pregnancy test within 48 hour prior time randomization must use contraceptive agent 11 . Unable unwilling consent component protocol . Patients unwilling undergo 6month followup enrol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>Chronic systolic heart failure</keyword>
	<keyword>Heart Failure</keyword>
</DOC>